Arbutus Biopharma Faces Patent Dispute and Catalysts from Imdusiran.

Arbutus Biopharma is facing a patent dispute with Moderna and has a busy few months ahead with near-term catalysts, including litigation and the potential approval of imdusiran. The company's stock has declined by about 10% in the last month.